Gastrointestinal
Implantica gears up for FDA approval of acid reflux device
Implantica has started the premarket approval process with the US Food and Drug Administration (FDA) for its gastroesophageal reflux disease…
Polpharma looks to challenge Takeda’s Entyvio in IBD
Netherland-based Polpharma Biologics has released topline results from a pharmacokinetic (PK) and pharmacodynamic (PD) study of its biosimilar candidate PB016,…
Inventiva halt recruitment for Phase III NASH trial following adverse event
French biopharmaceutical company, Inventiva has paused recruitment for its pivotal Phase III trial for lanifibranor after a trial participant reported…
Insilico’s AI-discovered ulcerative colitis drug starts Phase I trial
Hong Kong-based Insilico Medicine has launched a Phase I trial of its artificial intelligence (AI)-discovered drug ISM5411. The Phase I…
Pipeline Moves: Approval prospects drop for Bayer’s cardiovascular drug after Phase III termination
This week on Pipeline Moves, we kick off by looking at Phase III trial terminations by Bayer and Johnson &…
Sosei to regain rights to IBD drug after GSK discontinues programme
Sosei Group Corporation has initiated discussions to regain full ownership of the oral inflammatory bowel disease (IBD) drug GSK4381406 from…
InDex Pharmaceuticals terminates Phase III cobitolimod trial
InDex Pharmaceuticals has announced the termination of a Phase III trial of its candidate cobitolimod in patients with ulcerative colitis…
Chimeric to begin gastrointestinal cancer therapy trial
Chimeric Therapeutics has announced plans to commence a Phase IA/B clinical trial of CHM 2101 to treat gastrointestinal cancers. The…
Biora submits updated IND application for ulcerative colitis drug/device trial
Biora Therapeutics has submitted an updated investigational new drug (IND) application with the US Food and Drug Administration (FDA) for…
Phanes and Merck to study PT886 in combination with KEYTRUDA
US-based biopharmaceutical company Phanes Therapeutics has signed a clinical collaboration agreement with Merck, known as MSD outside North America, to…
